Knowledge and capabilities for products/services development: the UK spin-off firms context

Purpose – This article explores and investigates the skills and capabilities required in developing products and services within UK university spin-offs (USOs) by considering the model of products/services development (Verona, 1999). Design/methodology approach – mixed methods of 20 in-depth interviews and questionnaire survey with 204 founders of USOs. Findings – The findings contribute in filling the literature gap by demonstrating key knowledge and capabilities required to develop products/services within the unique and non-commercial context, in which USOs are created by academics who do not necessarily have entrepreneurial or business experience. Originality/value – This research contributes to studies of product/service development by adapting and modifying elements within the existing theoretical model to be applicable to the specific firm and country context, such as USOs in the UK. Further, the study extends knowledge on the interplay between knowledge management and product development. The applications of the findings are that they can inform academic entrepreneurs on the capabilities significant in the development process. They can also act as indicators to Technology Transfer Office (TTOs) in what is needed for the provision of appropriate support and training to academic founders/entrepreneurs in order to foster and enhance other entrepreneurial activities

Characteristics and outputs of university spin-offs in the United Kingdom

Research on the formal role of universities in stimulating regional economic development is relatively recent. However, the role of universities in contributing to regional technological and service variety is underresearched. In this study, we use a data set that has wide geographic coverage. The analysis provides a comprehensive understanding of the UK-wide contribution of university spin-offs (USOs) to the innovation capacity of their host regional economies. We argue that the survival and growth of USOs imply embeddedness in innovation ecosystems in a region. The findings show that the majority of firms in the sample are relatively young, small in size, and are still at the early stages of their life cycle. Hence, the products and services that are offered are fairly small in number. Nevertheless, their products/services based on university research have the potential for value capture by other firms thus implying contributions to a range of related and unrelated industry sectors within a region or beyond the local

Key driving factors for product and service innovations in UK university spinoffs

University spin-offs (USOs) are a vital firm class since they are an economically important sub-group of high-tech start-up firms. They have engendered a high volume of academic studies. However, what the firms deliver by way of innovation in the form of new products and services has largely been missing from the academic entrepreneurship literature. By adopting mixed research methodology of in-depth interviews and survey, this study demonstrates the important factors associated with the success of products and services development by university spin-off firms in the UK, such as understanding needs of customers, networks, clear market analysis, application of technology, and vision, mission and value of the company. The findings resonate with various studies in innovation management on the key elements of the products and services performance predictors. It also contributes to filling a gap in the academic entrepreneurship literature by providing an understanding beyond the success factors in setting up USOs. This can raise awareness and benefit actors at different levels, e.g., academic entrepreneurs and Technology Transfer Offices (TTOs) on the provision of actions and skills required to successfully develop products/services

Neonatal androgenization of hypogonadal (hpg) male mice does not abolish estradiol-induced FSH production and spermatogenesis

BACKGROUND: Testicular development is arrested in the hypogonadal (hpg) mouse due to a congenital deficiency in hypothalamic gonadotropin-releasing hormone (GnRH) synthesis. Chronic treatment of male hpg mice with estradiol induces FSH synthesis and secretion, and causes testicular maturation and qualitatively normal spermatogenesis. As estradiol negative feedback normally inhibits FSH production in the male, this study tested whether this paradoxical response to estradiol in the male hpg mouse might be due to inadequate masculinisation or incomplete defeminization in the neonatal period. Previous studies have demonstrated that treatment of hpg mice with testosterone propionate in the immediate neonatal period is necessary to allow full reproductive behaviors to be expressed following suitable endocrine stimulation at adult ages. METHODS: Hpg mice were treated with 100 μg testosterone propionate or vehicle on postnatal day 2. At 35 days of age, subgroups of these mice were treated with silastic implants containing estradiol or cholesterol. Reproductive behavior was scored in tests with steroid-primed female mice, then testicular development was assessed histologically, and measures of pituitary FSH content made at 85 days of age. RESULTS: The neonatal testosterone propionate treatment successfully defeminized female litter mates, as revealed by impaired vaginal opening and deficiencies in lordosis behavior, and it allowed appropriate male reproductive behavior to be expressed in a proportion of the hpg males when tested at an adult age. However, neonatal androgen supplementation did not block or even reduce the subsequent actions of estradiol in increasing pituitary FSH content, nor did it affect the ability of estradiol to induce qualitatively normal spermatogenesis. CONCLUSION: The ability of the hpg male to show a "female" neuroendocrine response to estradiol is not a result of inadequate androgenization during neonatal development, and thus the actions of estradiol revealed in this rodent model are not an artefact of incomplete sexual differentiation, but reflect a physiological role of estradiol occurring during a specific early temporal window of male reproductive development

Effects of estradiol and FSH on maturation of the testis in the hypogonadal (hpg) mouse

<p>Abstract</p> <p>Background</p> <p>The hypogonadal (hpg) mouse is widely used as an animal model with which to investigate the endocrine regulation of spermatogenesis. Chronic treatment of these GnRH-deficient mice with estradiol is known to induce testicular maturation and restore qualitatively normal spermatogenesis. The aim of the current studies was to investigate whether these effects of estradiol are direct effects in the testis, or indirect actions via paradoxical stimulation of FSH secretion from the pituitary gland.</p> <p>Methods</p> <p>Initially, Western blot and immunohistochemistry were used to analyse tissues from hpg mice to identify potential sites of action of estradiol. In the main study, hpg mice were treated for 50 days with either an estradiol implant or daily injections of recombinant human FSH, or a combination of both, to determine whether estradiol would have an additive or synergistic effect with FSH on testis development, as assessed by histological analysis and stereological quantification of Leydig, Sertoli and germ cell proliferation.</p> <p>Results</p> <p>Western blot analysis revealed ERα immunoreactive bands of appropriate molecular weight in extracts of testis and pituitary glands from hpg mice, and immunohistochemical studies confirmed ERα in nuclei of anterior pituitary cells and Leydig and peritubular cells in hpg mice. Histological and morphometric analyses revealed that estradiol treatment alone was as effective as FSH in promoting Sertoli cell production and proliferation of the seminiferous epithelium, resulting in the production of elongating spermatids. Combined estradiol and FSH treatment did not produce a greater effect than either treatment alone, though an increased dose of FSH significantly increased seminiferous tubule volume and testis weight and increase Sertoli cell numbers further within the same time frame. In contrast, estradiol caused substantial increases in the wet weight of the seminal vesicles, whereas FSH was without effect on this tissue, and did not augment the actions of estradiol.</p> <p>Conclusion</p> <p>As ERalpha receptor is abundantly expressed in the pituitary gland of hpg mice, and estradiol did not exert effects on testis development over and above those of FSH, we conclude that the action of estradiol on testis development in <it>hpg </it>mice is predominantly via the stimulation of pituitary FSH release.</p

Computer assisted orthopaedic surgery : past, present and future

Computer technology is ubiquitous and relied upon in virtually all professional activities including neurosurgery, which is why it is surprising that it is not the case for orthopaedic surgery with fewer than 5% of surgeons using available computer technology in their procedures. In this review, we explore the evolution and background of Computer Assisted Orthopaedic Surgery (CAOS), delving into the basic principles behind the technology and the changes in the discussion on the subject throughout the years and the impact these discussions had on the field. We found evidence that industry had an important role in driving the discussion at least in knee arthroplasty-a leading field of CAOS-with the ratio between patents and publications increased from approximately 1:10 in 2004 to almost 1:3 in 2014. The adoption of CAOS is largely restrained by economics and ergonomics with sceptics challenging the accuracy and precision of navigation during the early years of CAOS moving to patient functional improvements and long term survivorship. Nevertheless, the future of CAOS remains positive with the prospect of new technologies such as improvements in image-guided surgery, enhanced navigation systems, robotics and artificial intelligence

“Anyone can co-design?”: A case study synthesis of six experience-based co-design (EBCD) projects for healthcare systems improvement in New South Wales, Australia

Experience-based co-design (EBCD) is a quality improvement approach that is being used internationally to bring service users and health professionals together to improve healthcare experiences, systems and processes. Early evaluations and case studies of EBCD have shown promise in terms of improvements to experience and organisational processes, however challenges remain in participation around shared power and decision making, mobilisation for implementation, sustainment of improvements and measurement of outcomes. The objective of this case study was to explore the emergent issues in EBCD participation and implementation in six quality improvement projects conducted in mental health, rehabilitation, blood and bone marrow transplant, brain injury rehabilitation, urinary incontinence and intellectual disability settings by the Agency for Clinical Innovation (ACI), New South Wales, Australia (2015-2018). Methods: A two stage process of analysis was employed. The first stage involved a case to case synthesis using a variable-oriented approach. In this approach themes were identified within individual cases and compared across cases in workshops with all project leads. In the second stage the case themes were synthesised within an overarching thematic that was identified as the main challenge in effective participation and implementation in these EBCD projects. The results: themes identified in the first stage of analysis related to different methods for gathering experiences and the activities used for the co-design of improvements. Variability in service user participation within co-design workshops was also discussed. Four out of the six projects implemented improvements in full. The prominent thematic overarching all six EBCD cases was the need for guidance on capability development and co-design preparedness for all participants in co-design not only project leads. In conclusion, variability in EBCD implementation makes it difficult to identify which component parts are essential for improving experiences and services, and which of these lead to sustained changes and benefits for service users and health professionals. One way to address this is to develop a model for co-design capability and preparedness that is closely linked with a set of eight mechanisms that have been previously identified as essential to achieving change in healthcare improvement initiatives. Experience Framework This article is associated with the Innovation & Technology lens of The Beryl Institute Experience Framework. (http://bit.ly/ExperienceFramework) Access other PXJ articles related to this lens. Access other resources related to this len

Computer and robotic assisted orthopaedic knee arthroplasty surgery who drives innovations?

Computer assisted and Robotic technology in orthopaedic surgery is still not commonplace compared to un-assisted, conventional orthopaedic surgery. It may be considered somewhat surprising therefore, at a time of incredible technological progress that the computer still struggles nowadays to make its way in all orthopaedic theatres of the world.[1, 2] In June 2016, Dalton et al.[3] reviewed all patents and papers published between 1980 and 2014 related to knee surgery and sorted them into four clusters of innovations, which could be used to link patents and publications: Unicompartmental Knee Arthroplasty (UKA), Patient Specific Instrumentation (PSI), Navigation and Robotics. Three of these are part of the CAOS technology “family”. Since 2004, the ratio between patents and publications increased from approximately 1: 10 in 2004 to almost 1: 3 in 2014 showing industry-driven innovation on technology introduction in the field of knee arthroplasty

Computer and robotic assisted orthopaedic knee arthroplasty surgery : did CAOS technologies have an impact on the mainstream principles and concepts in the orthopaedic knee forum? A case study on alignment and balancing for TKA

Computer technology is ubiquitous and relied upon in virtually all professional activities. Confounding this is orthopaedic surgery where less than 5% of surgeons are using computer-assisted technologies routinely. However, the impact of Computer Assisted Orthopaedic Surgery (CAOS) may go beyond adoption in theatre. We searched pubmed for all knee arthroplasty papers concerning knee alignment and balancing between 1976 and 2016, dividing the results into those related to CAOS and those not. Results were grouped by technology. Between 2001 and 2008, the number of publications regarding knee navigation multiplied by 20 mainly focused on this topic of alignment and balancing, with alignment papers paralleled between navigation and non-navigation until 2010. After 2010, when navigation publications decline the number of articles related to the knee alignment and balancing without navigation increased granting the value of assessing accurately intraoperative kinematic data to improve Total Knee Arthroplasty (TKA) outcomes. From 2008, patient specific instrumentation (PSI) publications greatly increase, but navigation decreases, while robotic publications rise from 2014. CAOS surgery publications on the search topic of alignment and balancing increased greatly between 2001 and 2018 which may suggest the impact of CAOS technology on this important knee orthopaedic forum segment

A clinical and economic evaluation of Control of Hyperglycaemia in Paediatric intensive care (CHiP): a randomised controlled trial.

BACKGROUND: Early research in adults admitted to intensive care suggested that tight control of blood glucose during acute illness can be associated with reductions in mortality, length of hospital stay and complications such as infection and renal failure. Prior to our study, it was unclear whether or not children could also benefit from tight control of blood glucose during critical illness. OBJECTIVES: This study aimed to determine if controlling blood glucose using insulin in paediatric intensive care units (PICUs) reduces mortality and morbidity and is cost-effective, whether or not admission follows cardiac surgery. DESIGN: Randomised open two-arm parallel group superiority design with central randomisation with minimisation. Analysis was on an intention-to-treat basis. Following random allocation, care givers and outcome assessors were no longer blind to allocation. SETTING: The setting was 13 English PICUs. PARTICIPANTS: Patients who met the following criteria were eligible for inclusion: ≥ 36 weeks corrected gestational age; ≤ 16 years; in the PICU following injury, following major surgery or with critical illness; anticipated treatment > 12 hours; arterial line; mechanical ventilation; and vasoactive drugs. Exclusion criteria were as follows: diabetes mellitus; inborn error of metabolism; treatment withdrawal considered; in the PICU > 5 consecutive days; and already in CHiP (Control of Hyperglycaemia in Paediatric intensive care). INTERVENTION: The intervention was tight glycaemic control (TGC): insulin by intravenous infusion titrated to maintain blood glucose between 4.0 and 7.0 mmol/l. CONVENTIONAL MANAGEMENT (CM): This consisted of insulin by intravenous infusion only if blood glucose exceeded 12.0 mmol/l on two samples at least 30 minutes apart; insulin was stopped when blood glucose fell below 10.0 mmol/l. MAIN OUTCOME MEASURES: The primary outcome was the number of days alive and free from mechanical ventilation within 30 days of trial entry (VFD-30). The secondary outcomes comprised clinical and economic outcomes at 30 days and 12 months and lifetime cost-effectiveness, which included costs per quality-adjusted life-year. RESULTS: CHiP recruited from May 2008 to September 2011. In total, 19,924 children were screened and 1369 eligible patients were randomised (TGC, 694; CM, 675), 60% of whom were in the cardiac surgery stratum. The randomised groups were comparable at trial entry. More children in the TGC than in the CM arm received insulin (66% vs. 16%). The mean VFD-30 was 23 [mean difference 0.36; 95% confidence interval (CI) -0.42 to 1.14]. The effect did not differ among prespecified subgroups. Hypoglycaemia occurred significantly more often in the TGC than in the CM arm (moderate, 12.5% vs. 3.1%; severe, 7.3% vs. 1.5%). Mean 30-day costs were similar between arms, but mean 12-month costs were lower in the TGC than in CM arm (incremental costs -£3620, 95% CI -£7743 to £502). For the non-cardiac surgery stratum, mean costs were lower in the TGC than in the CM arm (incremental cost -£9865, 95% CI -£18,558 to -£1172), but, in the cardiac surgery stratum, the costs were similar between the arms (incremental cost £133, 95% CI -£3568 to £3833). Lifetime incremental net benefits were positive overall (£3346, 95% CI -£11,203 to £17,894), but close to zero for the cardiac surgery stratum (-£919, 95% CI -£16,661 to £14,823). For the non-cardiac surgery stratum, the incremental net benefits were high (£11,322, 95% CI -£15,791 to £38,615). The probability that TGC is cost-effective is relatively high for the non-cardiac surgery stratum, but, for the cardiac surgery subgroup, the probability that TGC is cost-effective is around 0.5. Sensitivity analyses showed that the results were robust to a range of alternative assumptions. CONCLUSIONS: CHiP found no differences in the clinical or cost-effectiveness of TGC compared with CM overall, or for prespecified subgroups. A higher proportion of the TGC arm had hypoglycaemia. This study did not provide any evidence to suggest that PICUs should stop providing CM for children admitted to PICUs following cardiac surgery. For the subgroup not admitted for cardiac surgery, TGC reduced average costs at 12 months and is likely to be cost-effective. Further research is required to refine the TGC protocol to minimise the risk of hypoglycaemic episodes and assess the long-term health benefits of TGC. TRIAL REGISTRATION: Current Controlled Trials ISRCTN61735247. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 18, No. 26. See the NIHR Journals Library website for further project information